Clinical Commander

Back to dossier
cardio.cardiogenic-shock.post-pacemaker-implant.v1PRODUCTION
cardio.cardiogenic-shock.post-pacemaker-implant.v1

Cardiogenic shock — Post pacemaker / ICD / CRT implantation

cardiologyacuteadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Post-PPM/ICD/CRT CS = differential of cardiac perforation tamponade (most common dangerous, 0.5-1%), pneumothorax with PEA, lead dislodgement with loss of capture (esp pacemaker-dependent), air embolism (venous access deep inspiration; cerebral via PFO; coronary), vagal-mediated transient hypotension, pocket hematoma with tamponade physiology

Inputs
2
Actions
0
Advance rule
Set
Advance when

EP + cardiology + interventional team activated

Patient inputs (11)

eGFR for drug dosing + contrast if re-imaging needed

Pre-procedure DOAC/warfarin/heparin status governs hematoma + tamponade risk and reversal decisions

Pacemaker-dependent patients (CHB, AV-junction-ablated) develop asystolic arrest if loss of capture from lead dislodgement

CVP elevation differentiates tamponade (high CVP + equalization) and tension PTX from vasovagal hypotension

STAT bedside echo: rule out pericardial effusion + chamber compression (lead perforation tamponade); confirm LV/RV function; assess lead position if visible

CXR for lead tip position (outside cardiac silhouette = perforation), pneumothorax (ipsilateral apex), hemothorax, and lead dislodgement

Capture confirmation (paced QRS morphology; loss of capture → lead dislodgement); ischemia/infarct from coronary air embolism

Lead impedance (high → fracture/dislodgement/perforation; low → insulation breach), R/P-wave amplitude (low → dislodgement), pacing threshold (high → perforation/dislodgement), capture confirmation

SBP <90 sustained drives shock-trigger threshold; PEA from tension PTX presents with profound hypotension

Lactate trend marks SCAI Stage C+; rising lactate confirms low CO state

Troponin elevation may indicate myocardial perforation or coronary air embolism

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (6)

6 need judgement
  • informationallife_threateningpost_pacemaker_lead_perforation_tamponade
    Post-PPM/ICD/CRT patient with new pericardial effusion + chamber compression on STAT echo + JVD + hypotension → emergent pericardiocentesis
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningpost_pacemaker_tension_pneumothorax_with_pea
    Post-PPM/ICD/CRT patient (especially after subclavian access) with hypoxemia + hypotension + tracheal deviation + ipsilateral hyperresonance + absent breath sounds → tension PTX with PEA
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningpost_pacemaker_dependent_loss_of_capture
    Pacemaker-dependent patient (CHB, AV-junction-ablated) with abrupt syncope, asystolic arrest, or symptomatic bradycardia → loss of capture from lead dislodgement
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningpost_pacemaker_cerebral_air_embolism
    Post-CIED patient with sudden focal neuro deficit, altered mental status, or seizure during/after venous access → cerebral air embolism
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepost_pacemaker_hematoma_with_tamponade_on_doac
    Post-CIED patient on uninterrupted DOAC/warfarin with large expanding pocket hematoma + hemodynamic compromise from extension or tamponade physiology
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverelate_lead_perforation_delayed_1_4_weeks
    Post-CIED patient with delayed presentation 1-4 weeks post-implant with chest pain + dyspnea + new pericardial effusion → late lead perforation
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Post-PPM/ICD/CRT CS — etiology-tailored regimen (perforation tamponade / pneumothorax / lead dislodgement / air embolism / hematoma / vagal)
axis: post_pacemaker_implant_cs_phenotype
Selected axis "Post-PPM/ICD/CRT CS — etiology-tailored regimen (perforation tamponade / pneumothorax / lead dislodgement / air embolism / hematoma / vagal)" by default fallback (first axis)
  • norepinephrine
    first line
    alpha_beta_pressor
    0.05-0.5 mcg/kg/min IV titrate to MAP ≥65 • IV • continuous
    triggers: post_pacemaker_hypotension
    SOAP-II PMID 20200382 — first-line vasopressor; lower arrhythmia than dopamine
    rxcui 7512
  • isoproterenol
    first line
    beta_agonist_chronotrope
    2-10 mcg/min IV titrate to HR 60-80 • IV • continuous
    triggers: pacemaker_dependent_loss_of_capture_bridge, lead_dislodgement_with_bradycardia
    Beta1/2 agonist increases sinus rate and AV conduction; bridge while transcutaneous pacing in place and EP lab readied for lead repositioning
    rxcui 6054
  • atropine
    first line
    anticholinergic
    0.5-1 mg IV q3-5 min, max 3 mg • IV • PRN
    triggers: vagal_mediated_bradycardia_hypotension
    Blocks vagal tone; effective for vagally-mediated bradycardia during sheath manipulation; ineffective for high-grade AV block from lead dislodgement
    rxcui 1223
  • idarucizumab
    second line
    dabigatran_reversal
    5 g IV (two 2.5 g vials) • IV • once
    triggers: pocket_hematoma_with_tamponade_on_dabigatran
    Specific dabigatran reversal; rapid onset; reduces bleeding-related morbidity
    rxcui 1716191
  • andexanet alfa
    second line
    factor_xa_reversal
    Low dose (400 mg bolus + 4 mg/min × 120 min) or High dose (800 mg + 8 mg/min × 120 min) per ANNEXA-4 dosing • IV • bolus + infusion
    triggers: pocket_hematoma_with_tamponade_on_apixaban_rivaroxaban
    Specific Factor Xa inhibitor reversal; expensive; reserve for life-threatening bleeding
    rxcui 2045114
  • four-factor PCC
    second line
    prothrombin_complex_concentrate
    25-50 IU/kg IV • IV • once
    triggers: pocket_hematoma_with_tamponade_on_warfarin
    Rapid VKA reversal; faster than FFP; preferred per ACC 2017 expert consensus on AC reversal
    rxcui 1670383
  • vasopressin
    second line
    v1_agonist
    0.03-0.04 U/min fixed • IV • continuous
    triggers: refractory_hypotension_after_ne
    V1 vasoconstriction add-on if NE >0.3 mcg/kg/min and persistent shock
    rxcui 11149

outpatient playbook — drug actions (1)

  1. 1. continue AC per usual indication
    rxcui 11289
    per usual • PO • as scheduled
    trigger: AF or other indication
    Standard AC

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Hours-to-days post-PPM/ICD/CRT implant: SBP <90 + tachycardia + signs of low CO; STAT echo: new pericardial effusion with chamber compression — cardiac perforation tamponade; Post-procedure CXR: ipsilateral pneumothorax (especially after subclavian access).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiogenic shock — Post pacemaker / ICD / CRT implantation** (cardio.cardiogenic-shock.post-pacemaker-implant.v1).
Scope: Post-PPM/ICD/CRT CS = differential of cardiac perforation tamponade (most common dangerous, 0.5-1%), pneumothorax with PEA, lead dislodgement with loss of capture (esp pacemaker-dependent), air embolism (venous access deep inspiration; cerebral via PFO; coronary), vagal-mediated transient hypotension, pocket hematoma with tamponade physiology

No severity triggers fired against current inputs.

Plan

Regimen axis: **Post-PPM/ICD/CRT CS — etiology-tailored regimen (perforation tamponade / pneumothorax / lead dislodgement / air embolism / hematoma / vagal)**.
1. norepinephrine 0.05-0.5 mcg/kg/min IV titrate to MAP ≥65 IV continuous (alpha_beta_pressor, first line) — SOAP-II PMID 20200382 — first-line vasopressor; lower arrhythmia than dopamine
2. isoproterenol 2-10 mcg/min IV titrate to HR 60-80 IV continuous (beta_agonist_chronotrope, first line) — Beta1/2 agonist increases sinus rate and AV conduction; bridge while transcutaneous pacing in place and EP lab readied for lead repositioning
3. atropine 0.5-1 mg IV q3-5 min, max 3 mg IV PRN (anticholinergic, first line) — Blocks vagal tone; effective for vagally-mediated bradycardia during sheath manipulation; ineffective for high-grade AV block from lead dislodgement
4. idarucizumab 5 g IV (two 2.5 g vials) IV once (dabigatran_reversal, second line) — Specific dabigatran reversal; rapid onset; reduces bleeding-related morbidity
5. andexanet alfa Low dose (400 mg bolus + 4 mg/min × 120 min) or High dose (800 mg + 8 mg/min × 120 min) per ANNEXA-4 dosing IV bolus + infusion (factor_xa_reversal, second line) — Specific Factor Xa inhibitor reversal; expensive; reserve for life-threatening bleeding
6. four-factor PCC 25-50 IU/kg IV IV once (prothrombin_complex_concentrate, second line) — Rapid VKA reversal; faster than FFP; preferred per ACC 2017 expert consensus on AC reversal
7. vasopressin 0.03-0.04 U/min fixed IV continuous (v1_agonist, second line) — V1 vasoconstriction add-on if NE >0.3 mcg/kg/min and persistent shock

Setting playbook (outpatient) — Long-term CIED management: routine device interrogation per device-specific cadence; AC management for AF or other indication; monitoring for delayed lead complications
8. continue AC per usual indication per usual PO as scheduled — AF or other indication (Standard AC)

Non-pharmacologic actions:
- Routine remote monitoring
- EP visits per device-specific cadence
- Patient education on device alarms + signs of complications

AVOID / contraindication checks:
- Avoid_ppv_in_tamponade_until_drained (worsens cardiac filling and CO)
- Emergent_pericardiocentesis_for_tamponade_no_delay (mortality scales with delay)
- Emergent_needle_decompression_for_tension_ptx (do not wait for CXR)
- Transcutaneous_pacing_and_isoproterenol_bridge_for_pacemaker_dependent_loss_of_capture
- Hyperbaric_o2_for_cerebral_air_embolism_within_6h_window (best outcomes)
- Do_not_attempt_lead_extraction_at_bedside (specialized procedure with cardiothoracic backup)
- Trendelenburg_and_left_lateral_decubitus_for_air_embolism (traps air in RV apex)
- Reverse_anticoagulation_only_if_life_threatening_bleed (weigh thrombotic risk)

Monitoring

Regimen monitoring:
- continuous telemetry + a line + central line
- repeat echo q4 6h first 24h post tamponade drainage
- serial cxr for lung re expansion if chest tube
- device interrogation daily for lead stability
- inr anti xa q4 6h if ac reversed
- lactate + abg q2h until clearing
- cbc + coag q4h if active bleeding
- neuro checks q1h if cerebral air embolism suspected

Setting (outpatient) monitoring:
- Device interrogation per cadence

Follow-up plan: Pre-discharge device interrogation + CXR + echo; close EP follow-up at 1-2 weeks; restart anticoagulation per device-procedure-specific protocol; patient education on signs of late perforation (delayed up to 4 weeks)
- Close-out criterion: EP follow-up + AC plan documented

Monitoring phase: Continuous telemetry + a-line + repeat echo q4-6h for first 24h post-tamponade; serial CXR for re-expansion of lung; daily device interrogation for lead stability; INR/anti-Xa if anticoagulation reversed

Disposition

Current setting: outpatient — Long-term CIED management: routine device interrogation per device-specific cadence; AC management for AF or other indication; monitoring for delayed lead complications

Disposition criteria:
- Long-term continuation; cross-link to cardio.afib.core.v1 if AF, cardio.hf.core.v1 if HFrEF

Escalation triggers (move to higher acuity):
- Device alarm or low battery → EP urgent
- Late lead complication → EP service

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Post-PPM/ICD/CRT patient with new pericardial effusion + chamber compression on STAT echo + JVD + hypotension → emergent pericardiocentesis
- [LIFE_THREATENING] Post-PPM/ICD/CRT patient (especially after subclavian access) with hypoxemia + hypotension + tracheal deviation + ipsilateral hyperresonance + absent breath sounds → tension PTX with PEA
- [LIFE_THREATENING] Pacemaker-dependent patient (CHB, AV-junction-ablated) with abrupt syncope, asystolic arrest, or symptomatic bradycardia → loss of capture from lead dislodgement

Citations

- HRS 2024 CIED Complications Statement + 2018 ACC/AHA/HRS Bradycardia and Cardiac Conduction Delay Guideline + SCAI 2022 CS staging (Naidu PMID 35718438) [PMID:35718438](https://pubmed.ncbi.nlm.nih.gov/35718438/)
- Cited evidence (PMID 20200382) [PMID:20200382](https://pubmed.ncbi.nlm.nih.gov/20200382/)
- Cited evidence (PMID 30412709) [PMID:30412709](https://pubmed.ncbi.nlm.nih.gov/30412709/)
- Cited evidence (PMID 20691317) [PMID:20691317](https://pubmed.ncbi.nlm.nih.gov/20691317/)
- Cited evidence (PMID 15922271) [PMID:15922271](https://pubmed.ncbi.nlm.nih.gov/15922271/)

Last reconciled with current guidelines: 2026-05-15.
References
  • HRS 2024 CIED Complications Statement + 2018 ACC/AHA/HRS Bradycardia and Cardiac Conduction Delay Guideline + SCAI 2022 CS staging (Naidu PMID 35718438) — PMID:35718438
  • Cited evidence (PMID 20200382) — PMID:20200382
  • Cited evidence (PMID 30412709) — PMID:30412709
  • Cited evidence (PMID 20691317) — PMID:20691317
  • Cited evidence (PMID 15922271) — PMID:15922271